Dr Forsberg on the Impact of the MajesTEC-3 Trial in Relapsed/Refractory Myeloma

"There are a lot of layers to [the MajesTec-3 trial results], but [the data] are unequivocally impactful and will help [the coMMit consortium] move positive outcomes forward for patients across the early relapsed/refractory myeloma setting.”

Peter Forsberg, MD, an associate member physician of myeloma and plasma cell disorders at the Colorado Blood Cancer Institute, discussed how data from the phase 3 MajesTEC-3 trial (NCT05083169) presented at the 2025 ASH Annual Meeting and Exposition could affect the management of relapsed/refractory multiple myeloma. He also spotlighted key takeaways from the coMMit Consortium held during ASH 2025, which sought to interpret and contexualize key multiple myeloma data to emerge from this year's conference.

Forsberg dove into conversations that followed the review of the data from the MajesTEC-3 trial, including how the results might affect future approaches to both patient care and research for the coMMit Consortium. Forsberg pointed out that the significant improvements in the 36-month overall survival (OS; 83.3% vs 65.0%) and progression-free survival (PFS; 83.4% vs 29.7%) rates for teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) compared with standard daratumumab-based regimens might influence the type of research that the coMMit Consortium will move toward in the future.

However, Forsberg also said that there is notable nuance to these results, as many of the patients from the study had less exposure to monoclonal antibody therapy vs other patients who were not enrolled. Forsberg noted that these differences in baseline characteristics might prompt a different interpretation of the data from the trial; nonetheless, he explained that the results are still impactful.

Forsberg mentioned that the coMMit Consortium is a collaborative effort at its core, committed to conducting innovative trials that can fill gaps and move the myeloma field forward as a whole. Data for newly diagnosed and relapsed myeloma settings were important topics of discussion for the consortium, Forsberg stated. Forsberg also added that data in the early relapse myeloma setting might be the most pivotal in terms of initially influencing patient care.